The present invention relates to 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-ons and derivatives thereof, a method for producing the same, and a composition for prevention, improvement or treatment of neurodegenerative disease containing the same. Specifically, 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-ons and derivatives thereof, which are novel compounds of the present invention, can be used as an excellent composition for prevention, improvement or treatment of neurodegenerative disease.

The present invention relates to 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-ons and derivatives thereof, a method for producing the same, and a composition for prevention, improvement or treatment of neurodegenerative disease containing the same. Specifically, 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-ons and derivatives thereof, which are novel compounds of the present invention, can be used as an excellent composition for prevention, improvement or treatment of neurodegenerative disease.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

A light-emitting device includes a first electrode, a second electrode opposite to the first electrode, and an interlayer between the first electrode and the second electrode and including an emission layer, wherein the interlayer includes an organic compound including a first moiety represented by Formula 1 and a second moiety represented by Formula 2:

##STR00001## wherein, in Formulae 1 and 2, a moiety represented by is a single bond or a double bond, X.sub.11, X.sub.12, X.sub.21, and X.sub.22 are each independently O or S, Y.sub.11 is C, C(R.sub.13), or N, Z.sub.11 is C(R.sub.14), N, N(R.sub.14), O, or S, Y.sub.21 is C, C(R.sub.23), or N, Z.sub.21 is C(R.sub.24), N, N(R.sub.24), O, or S, R.sub.11 or R.sub.12 is a linking site to the second moiety, and R.sub.21 or R.sub.22 is a linking site to the first moiety.

A light-emitting device includes a first electrode, a second electrode opposite to the first electrode, and an interlayer between the first electrode and the second electrode and including an emission layer, wherein the interlayer includes an organic compound including a first moiety represented by Formula 1 and a second moiety represented by Formula 2:

##STR00001## wherein, in Formulae 1 and 2, a moiety represented by is a single bond or a double bond, X.sub.11, X.sub.12, X.sub.21, and X.sub.22 are each independently O or S, Y.sub.11 is C, C(R.sub.13), or N, Z.sub.11 is C(R.sub.14), N, N(R.sub.14), O, or S, Y.sub.21 is C, C(R.sub.23), or N, Z.sub.21 is C(R.sub.24), N, N(R.sub.24), O, or S, R.sub.11 or R.sub.12 is a linking site to the second moiety, and R.sub.21 or R.sub.22 is a linking site to the first moiety.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

##STR00001##

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

##STR00001##